RxDoctor Payments Data

Rosa Galvez, MD

Internal Medicine · Albuquerque, NMNPI 1821035437

Payments from drug & device makers

$1,139in general payments, 2019–2025

Across 78 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$258
  • Boehringer Ingelheim$148
  • AstraZeneca$126
  • Pfizer$100
  • Amgen$75
  • GSK$75
  • plus $357 from 12 others

What the payments were for

  • Food & beverage$1,12499%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,139 in reported general payments places this provider in the 85th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$177,894
Medicare patients
439
Services billed
2,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$114,021
OzempicSemaglutide91$107,923
MounjaroTirzepatide74$89,449
EliquisApixaban70$63,858
TrulicityDulaglutide51$54,470
JanuviaSitagliptin Phosphate52$48,108
XareltoRivaroxaban21$20,834
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,001
Levothyroxine Sodium576$7,443
Atorvastatin Calcium506$6,211
Rosuvastatin Calcium423$5,593
MovantikNaloxegol Oxalate12$5,001
SynthroidLevothyroxine Sodium81$4,967
BreynaBudesonide/Formoterol Fumarate19$4,793
Fluticasone Propionate HfaFluticasone Propionate17$4,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$63$143,919125 claims
Boehringer IngelheimJardiance$148$114,021118 claims
Novo NordiskOzempic$258$107,92391 claims
PfizerEliquis$100$63,85870 claims
MerckJanuvia$50$48,10852 claims
Johnson & JohnsonXarelto$13$20,83421 claims
GSKTrelegy Ellipta, Arnuity Ellipta$75$16,87929 claims
AbbVieSynthroid$39$4,96781 claims
AstraZenecaSymbicort$126$4,27412 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$51$3,71211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →